Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?
在佛羅里達州大麻股合法化的失敗後，MariMed是否是一個安全的避風港？
Cannabis company MariMed Inc. (NASDAQ:MRMD) released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%. These adjustments align closely with earlier projections from Zuanic & Associates, a cannabis industry research firm.
大麻公司MariMed Inc.（納斯達克股票代碼：MRMD）於11月6日發佈了其2024年第三季度業績，宣佈了該財年的修訂指引。儘管該公司預計息稅折舊攤銷前利潤將下降18-20％，低於之前預測的持平至2％的增長，但該公司將其銷售預期從5-7％上調至6-8％。這些調整與大麻行業研究公司Zuanic & Associates早些時候的預測非常吻合。
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the...
每天在收件箱中免費獲取Benzinga的獨家分析以及有關大麻行業和市場的熱門新...
登入免費觀看全文
登入/註冊
熱門討論
FOMC維持利率但不確定性高企：美股後市走向如何？
🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？
Moo Live
03/20 02:25
聯邦公開市場委員會新聞發佈會，2025年3月19日